OncoMatch/Clinical Trials/NCT06410651
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
Is NCT06410651 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Nimotuzumab with chemoradiotherapy for esophageal cancer.
Treatment: Nimotuzumab with chemoradiotherapy — Patients diagnosed with locally advanced esophageal squamous cell carcinoma (ESCC) who failed to induction chemo(immuno)therapy had poor prognosis. Radiotherpy was an important and effective treatment in treating ESCC. The present study is a one-arm trial that seeks to evaluate the efficacy in patients with unresectable ESCC. The study objectives include R0 resection rate, complete pathological response and treatment toxicity, etc. Nimotuzumab is a recombinant humanized monoclonal antibody against EGFR. Its efficacy and safety in patients with esophageal cancer have been confirmed by many studies. The current prospective phase II study aimed to evaluate the efficacy and safety of a combination regimen comprising chemotherapy with nimotuzumab and S-1 and concurrent radiotherapy for patients who are not sensitive to induction chemo(immuno)therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Prior therapy
Must have received: chemotherapy or immunotherapy — induction
Cycles of induction chemo(immuno)therapy was 2-4
Lab requirements
Blood counts
hemoglobin (Hb) ≥100g/L; absolute neutrophil count (NEUT)≥1.5×10^9/L; platelets (PLT) ≥100×10^9/L; white blood cell (WBC)≥3.5×10^9/L
Kidney function
serum creatinine (Cr) 1.0×1.5UNL, and BUN≤1.0×UNL
Liver function
ALT and AST ≤1.5×UNL; serum total bilirubin (TBIL) ≤1.5×UNL
Main organs and bone marrow function are normal: routine blood tests: hemoglobin (Hb) ≥100g/L ; absolute neutrophil count (NEUT)≥1.5×10^9/L; platelets (PLT) ≥100×10^9/L; white blood cell (WBC)≥3.5×10^9/L,biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5×UNL; serum total bilirubin (TBIL) ≤1.5×UNL; serum creatinine ( Cr) 1.0×1.5UNL, and BUN≤1.0×UNL;
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify